In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy

Session Cardiac phenotyping and outcome implications

Speaker Niccolo' Maurizi

Congress : ESC Congress 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Myocardial Disease - Epidemiology, Prognosis, Outcome
  • Session type : Abstract Session
  • FP Number : 145

Authors : N Maurizi (Florence,IT), M Michels (Rotterdam,NL), EJ Rowin (Boston,US), C Semsarian (Sydney,AU), F Girolami (Florence,IT), BJ Tomberli (Florence,IT), F Cecchi (Florence,IT), MS Maron (Boston,US), I Olivotto (Florence,IT), BJ Maron (Boston,US)

N. Maurizi1 , M. Michels2 , E.J. Rowin3 , C. Semsarian4 , F. Girolami5 , B.J. Tomberli5 , F. Cecchi5 , M.S. Maron3 , I. Olivotto5 , B.J. Maron3 , 1University of Florence, Department of Clinical and Experimental Medicine - Florence - Italy , 2Erasmus Medical Center - Rotterdam - Netherlands , 3Tufts Medical Center, Hypertrophic Cardiomyopathy Institute - Boston - United States of America , 4Royal Prince Alfred Hospital - Sydney - Australia , 5Careggi University Hospital (AOUC) - Florence - Italy ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 14

Background: Although common among families with hypertrophic cardiomyopathy (HCM), the clinical course and outcome of relatives with sarcomere mutations judged to be disease causing, but without left ventricular hypertrophy (LVH), is largely unresolved.

Objective: To determine the clinical features and natural history of genotype positive (+) –LVH negative (−) HCM.

Methods: Prospective analysis of G+LVH- individuals followed at 4 international referral centers for HCM. Participants were ≥12 years old at first evaluation and carried a pathogenic/likely pathogenic sarcomere variant considered to cause HCM in their family.

Results: Two-hundred and three individuals were identified from 158 HCM families. Age at first evaluation was 32±11 years and 147 (72%) were <40 years; 61% were female. Initially, each patient showed normal LV thickness and cavity dimensions with preserved systolic function. Maximal LV wall thickness was 9±2mm.

Over follow-up of 6±2 years, no adverse cardiovascular events such as death, heart failure, or cardiac symptoms occurred among the 203 patients; 182 (90%) remained without LVH, including 37 (20%) ≥50 years of age (including 5% ≥60 years, range to 69). Twenty-one patients (10%) converted to clinically evident HCM with LVH (maximum wall thickness ≥13mm range to 17mm) at 35±15 years of age (range 7 to 62 years). Of the 21 patients who developed LVH, 8 (38%) were >40 years old; rate of conversion was 0.3%/year, and similar across all age groups (p=0.76). 12-lead ECGs were abnormal in 10 patients (48%) at the time LV thickness was normal. Multivariate analysis showed pathologic Q waves to be an independent predictor for development of LVH (HR 2.1, 95% CI: 1.3–5.1, p=0.01).

Conclusions: G+LVH- patients demonstrated exceedingly low risk for mortality, morbidity, and HCM-related complications. Phenotypic conversion to HCM was uncommon, often preceded (4-years) by abnormal ECG patterns, with a large proportion of patients remaining free of LVH at relatively advanced ages, implying that many gene carriers may not develop HCM during their lifetime.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are